Daunorubicin Liposomal
Daunorubicin Liposomal is a chemotherapy medication encapsulated in liposomes (fatty particles) that delivers the active drug more selectively to cancer cells. It is primarily used to treat acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and has shown efficacy in HIV-related Kaposi's sarcoma. The liposomal formulation may help reduce certain side effects compared to conventional daunorubicin while maintaining anti-cancer activity.
A liposome-encapsulated anthracycline chemotherapy used primarily for acute leukemias that delivers targeted cancer-cell killing activity.
Key facts at a glance
- RxNorm
- 214468
- Generic
- Daunorubicin Liposomal
- Class
- pin-variant
- Brands
- Vyxeos
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Primarily used for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in both adults and children. Also used for HIV-associated Kaposi's sarcoma. May be used in combination with other chemotherapy agents depending on the specific treatment protocol.
An anthracycline antibiotic that works by intercalating (inserting) into DNA strands, inhibiting the enzyme topoisomerase II, and generating free radicals that damage cancer cell DNA. The liposomal encapsulation helps target drug delivery to tumor tissue and may improve accumulation at cancer sites while potentially reducing damage to healthy cells.
Administered intravenously only by qualified healthcare professionals. Can cause significant bone marrow suppression (low blood counts), cardiotoxicity requiring cardiac monitoring, and infusion-related reactions. May cause red-orange discoloration of urine, tears, and sweat. Pregnancy category D - contraindicated in pregnancy. Requires regular blood count monitoring and cardiac function assessment during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy